{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:46:05Z","timestamp":1782981965450,"version":"3.54.5"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa is a chronic inflammatory skin disease causing recurrent abscesses, tunnels, and scarring. Despite significant disease burden in children and adolescents, treatment data for this population remains limited. This review summarizes the most recent developments in pediatric hidradenitis suppurativa management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The 2025 North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special populations included key consensus-based treatment recommendations for pediatric hidradenitis suppurativa. Although antibiotics remain the mainstay of treatment for acute flares, adult data support the use of intravenous ertapenem as a rescue therapy for severe, recalcitrant hidradenitis suppurativa. Hormonal therapies, including spironolactone and combined oral contraceptives, should be considered in postmenarchal women. Metabolic therapies, particularly metformin and GLP-1 receptor agonists, are newer adjunctive options for patients with comorbid obesity and insulin resistance. Secukinumab was recently approved for moderate-to-severe hidradenitis suppurativa in adolescents at least 12\u200ayears, and clinical trials for multiple other biologic therapies for pediatric hidradenitis suppurativa are underway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Patients with pediatric hidradenitis suppurativa require individualized management approaches that consider their unique comorbidities and stages of development. Clinicians should integrate the 2025 North American guidelines into clinical practice, recognize, and co-manage comorbidities when appropriate, and counsel patients on approved and emerging biologic options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001590","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:00:10Z","timestamp":1781510410000},"page":"389-395","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the treatment of pediatric hidradenitis suppurativa: emerging therapies and future directions"],"prefix":"10.1097","volume":"38","author":[{"given":"Anastasia","family":"Chajecki","sequence":"first","affiliation":[{"name":"Children's National Hospital"},{"name":"George Washington University School of Medicine and Health Sciences, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen H.","family":"Cotton","sequence":"additional","affiliation":[{"name":"Children's National Hospital"},{"name":"George Washington University School of Medicine and Health Sciences, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpag.2025.09.007","article-title":"Hidradenitis suppurativa in the pediatric and adolescent population","volume":"39","author":"Hickerson","year":"2026","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/pde.70022","article-title":"Prevalence, age of onset, age at diagnosis, and family history of hidradenitis suppurativa in pediatric populations: a systematic review and meta-analysis","volume":"42","author":"Xiong","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamadermatol.2020.5435","article-title":"Hidradenitis suppurativa in the pediatric population: an international, multicenter, retrospective, cross-sectional study of 481 pediatric patients","volume":"157","author":"Liy-Wong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/pde.15574","article-title":"Pediatric hidradenitis suppurativa publication trends: 2012 to 2022","volume":"41","author":"Park","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"R8-20260702","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaad.2024.11.071","article-title":"North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations","volume":"92","author":"Alhusayen","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/ijd.16892","article-title":"Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa","volume":"62","author":"Henry","year":"2023","journal-title":"Int J Dermatol"},{"key":"R11-20260702","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"R12-20260702","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Mendon\u00e7a","year":"2006","journal-title":"Br J Dermatol"},{"key":"R13-20260702","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjd.19867","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa in patients of paediatric age: a pilot prospective study","volume":"185","author":"Bettoli","year":"2021","journal-title":"Br J Dermatol"},{"key":"R14-20260702","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2020.01.007","article-title":"Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients","volume":"88","author":"Delage","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R15-20260702","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamadermatol.2023.6201","article-title":"Efficacy and durability of intravenous ertapenem therapy for recalcitrant hidradenitis suppurativa","volume":"160","author":"Nosrati","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R16-20260702","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/ofid\/ofx163.115","article-title":"More than just an anti-infective agent: a prospective pilot clinical trial to determine the effectiveness of IV ertapenem in severe hidradenitis suppurativa","volume":"4","author":"Ramesh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R17-20260702","doi-asserted-by":"crossref","first-page":"785","DOI":"10.36849\/jdd.7325","article-title":"Hormonal treatments in hidradenitis suppurativa: a systematic review","volume":"22","author":"Masson","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"R18-20260702","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2025.1565","article-title":"Prevalence of comorbidities among pediatric patients with hidradenitis suppurativa: a meta-analysis","volume":"161","author":"Mohsen","year":"2025","journal-title":"JAMA Dermatol"},{"key":"R19-20260702","first-page":"697","article-title":"The role of oral contraceptive pills in hidradenitis suppurativa: a cohort study","volume":"11","author":"Montero-Vilchez","year":"2021","journal-title":"Life (Basel)"},{"key":"R20-20260702","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.det.2021.12.004","article-title":"Hormonal treatment of acne and hidradenitis suppurativa in adolescent patients","volume":"40","author":"Svoboda","year":"2022","journal-title":"Dermatol Clin"},{"key":"R21-20260702","first-page":"83","article-title":"Combined oral contraceptives for the treatment of acne: a practical guide","volume":"90","author":"Arrington","year":"2012","journal-title":"Cutis"},{"key":"R22-20260702","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0010-7824(90)90039-X","article-title":"Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins","volume":"41","author":"Phillips","year":"1990","journal-title":"Contraception"},{"key":"R23-20260702","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/TCRM.S6864","article-title":"Use of ethinylestradiol\/drospirenone combination in patients with the polycystic ovary syndrome","volume":"4","author":"Mathur","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R24-20260702","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2019.1592100","article-title":"Metformin use in hidradenitis suppurativa","volume":"31","author":"Jennings","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R25-20260702","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.36849\/JDD.2020.5447","article-title":"Metformin as adjunctive therapy for pediatric patients with hidradenitis suppurativa","volume":"19","author":"Moussa","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R26-20260702","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40257-024-00911-x","article-title":"Obesity in hidradenitis suppurativa: are GLP-1 receptor agonists the new frontier?","volume":"26","author":"Strong","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"R27-20260702","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"},{"key":"R28-20260702","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljae216","article-title":"Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life","volume":"191","author":"Lyons","year":"2024","journal-title":"Br J Dermatol"},{"key":"R29-20260702","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","article-title":"Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa","volume":"162","author":"Nicolau","year":"2024","journal-title":"Med Cl\u00edn (Barc)"},{"key":"R30-20260702","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/12034754211049711","article-title":"Biologic use in pediatric patients with hidradenitis suppurativa: a systematic review","volume":"26","author":"Sachdeva","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"R31-20260702","first-page":"520","article-title":"ADOLESBIO-HS: a real-world multicenter case series on the effectiveness and safety of adalimumab in adolescents with moderate-to-severe hidradenitis suppurativa","volume":"241","author":"Grau-P\u00e9rez","year":"2025","journal-title":"Dermatology"},{"key":"R33-20260702","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","article-title":"Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States","volume":"8","author":"Bergman","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R35-20260702","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/bjd\/ljae469","article-title":"Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial","volume":"192","author":"Kimball","year":"2025","journal-title":"Br J Dermatol"},{"key":"R47-20260702","article-title":"Surgical deroofing for the management of hidradenitis suppurativa: a systematic review and meta-analysis","author":"King","year":"2025","journal-title":"J Cutan Med Surg"},{"key":"R48-20260702","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/DSS.0000000000004604","article-title":"Surgical deroofing in the management of hidradenitis suppurativa alone or as an adjunct to medical therapies","volume":"51","author":"Vu","year":"2025","journal-title":"Dermatol Surg"},{"key":"R49-20260702","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/pde.14955","article-title":"Surgical deroofing in pediatric patients with hidradenitis suppurativa","volume":"39","author":"Leszczynska","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"R50-20260702","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ajd.14624","article-title":"Hidradenitis suppurativa deroofing surgery outcomes including pain scores, surface area reduction and patient satisfaction in an Australian Cohort","volume":"67","author":"Mortimore","year":"2026","journal-title":"Aust J Dermatol"},{"key":"R51-20260702","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/pde.70019","article-title":"Adolescent satisfaction after deroofing surgery for hidradenitis suppurativa","volume":"43","author":"Haller","year":"2026","journal-title":"Pediatr Dermatol"},{"key":"R52-20260702","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jaad.2025.08.024","article-title":"Prevalence of comorbidities among pediatric patients with hidradenitis suppurativa at a safety-net hospital","volume":"93","author":"Cole","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R53-20260702","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/pde.70054","article-title":"Comorbidities of pediatric patients with hidradenitis suppurativa in the emergency department setting: a cross-sectional study","volume":"43","author":"Hailemichael","year":"2026","journal-title":"Pediatr Dermatol"},{"key":"R54-20260702","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/ijd.70131","article-title":"Global patterns of comorbidities among patients with hidradenitis suppurativa: a systematic review and meta-analysis","volume":"65","author":"Gupta","year":"2026","journal-title":"Int J Dermatol"},{"key":"R55-20260702","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/pde.15983","article-title":"Characterizing disease severity, comorbidities, and treatment plans in pediatric hidradenitis suppurativa patients with and without obesity: a cohort and cross-sectional analysis","volume":"42","author":"Numani","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"R56-20260702","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4082\/kjfm.25.0018","article-title":"Association between depression and medication adherence in noncommunicable diseases: a narrative review","volume":"46","author":"Hisan","year":"2025","journal-title":"Korean J Fam Med"},{"key":"R57-20260702","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijwd.2020.02.006","article-title":"Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice","volume":"6","author":"Timila Touhouche","year":"2020","journal-title":"Int J Womens Dermatol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:00:26Z","timestamp":1782979226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001590","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}